The Psychedelic News Hour - New Breakthroughs, Treatment of Trauma, and More | The Tim Ferriss Show

Recorded on Clubhouse for the Psychedelic News Hour, this episode flips Tim Ferriss into the interviewee seat to discuss psychedelic-assisted psychotherapy and the future of mental health. They cover the freshly completed MAPS 'Capstone' campaign that raised $30 million to finish Phase 3 trials of MDMA-assisted therapy for PTSD, the science and study design behind these treatments, and the striking durability of the results. Ferriss repeatedly plays the conservative voice, stressing that psychedelics are not a panacea, that preparation and integration matter enormously, and that 90% of the time he advises people against DIY use. The conversation also explores scaling treatment access, why diverse philanthropic funding matters now, the stigma preventing licensed professionals from seeking mental-health care, and ethical risks like overly broad patents. It closes with audience Q&A on stress tracking, racism/sexism, COVID isolation, and navigating difficult trips.

• The MAPS 'Capstone' campaign raised $30 million to complete Phase 3 trials of MDMA-assisted psychotherapy for PTSD, with more than 2,500 donors giving from $1 up to $5 million.
  00:08:19
• In MDMA Phase 2 trials, patients with treatment-resistant PTSD for an average of 17 years saw about 53% no longer meeting diagnostic criteria after just three doses plus 12 weeks of psychotherapy.
  00:13:29
• At five years out with no further treatment, 67% of MDMA patients no longer met PTSD diagnostic criteria, while placebo-group responders often relapsed.
  00:13:59
• Ferriss says that after a few follow-up questions, 90%+ of the time his answer to 'should I do a psychedelic?' is no, because preparation and post-care are essential.
  00:25:54
• Ferriss describes his funding strategy: provide seed capital to de-risk and destigmatize, paving the way for foundations and federal funding, which he hopes arrives within three to five years.
  00:36:19
• Ferriss argues you don't need to treat 100 million people to change the world; helping one person overcome paralyzing trauma can have an enormous ripple effect.
  00:45:10
• On patents, Ferriss warns the most critical ethical risk is broad patent land-grabs that could lock up the field, and urges watchdog opposition at the patent office.
  01:15:36

• Rick Doblin/MAPS took roughly 30 years to raise their first $30 million, an amount the Capstone campaign matched in just a few years.
  00:08:51
• Acetaminophen (Tylenol) sends far more people to emergency rooms and carries higher toxicity than psilocybin or MDMA.
  00:11:56
• Blinding psychedelic studies is hard because participants can quickly tell they received an active drug; researchers use 'active placebos' like niacin to mimic physiological effects.
  00:19:38
• Belief is powerful: placebo can make treatment work 30-50% more often, while nocebo (believing it won't work) can make it 30-50% less likely to succeed.
  00:21:12
• MDMA must hit a threshold dose (roughly 80-120 mg) to be effective, making it a poor candidate for microdosing; sub-threshold doses were used as the placebo.
  00:23:19
• About 25-27% of the sub-therapeutic placebo group also lost their PTSD diagnosis at two months, showing the 12-week therapy alone is potent.
  00:23:50
• Ferriss notes we operated on newborns and infants without anesthesia until 1987, illustrating how much of accepted medicine later proves wrong.
  00:31:37
• Ferriss observes the psychedelic world's biggest weakness is lack of focus: 'if everything is your priority, nothing is your priority.'
  00:48:48
• Licensed professionals can lose their license for a mental-illness diagnosis on record, creating a paradox of untreated burnout among front-line caregivers.
  00:58:05
• There is no indigenous culture that progresses sequentially through psychedelics; these are not 'psychedelic cultures' but cultures that use plants for specific purposes like warfare and hunting.
  01:05:48